STAT

Avidity, FDA reach agreement on accelerated filing of rare disease drug

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Los Angeles Times

Avidity Biosciences to be Acquired by Novartis in $12-Billion Deal

This is read by an automated voice. Please report any issues or inconsistencies here. San Diego-based Avidity Biosciences Inc. agreed to be acquired by Novartis AG in a deal valued at $12 billion.
Nasdaq

Avidity Announces First Person Dosed with an Antibody Oligonucleotide Conjugate (AOC™)

Participant dosed with AOC 1001 in the Phase 1/2 MARINA™ trial in adults with myotonic dystrophy type 1 (DM1) LA JOLLA, Calif., Nov. 4, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a ...
Nasdaq

Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints ...

Avidity accelerates global Phase 3 HARBOR™ study initiation to Q2 2024 following regulatory agreement on study design; primary endpoint is video hand opening time (vHOT) and secondary endpoints ...